A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE)
A Phase 3 Multinational, Open-label, Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9003 in Subjects With Limb Girdle Muscular Dystrophy 2E/R4
Sponsor: Sarepta Therapeutics, Inc.
This PHASE3 trial investigates Limb-girdle Muscular Dystrophy and is currently ongoing. Sarepta Therapeutics, Inc. leads this study, which shows 10 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Mar 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Mar 2026 [monthly]
Active Not Recruiting PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Apr 2025 — May 2025 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Dec 2024 — Apr 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
Mar 2024 — Jun 2024 [monthly]
Recruiting PHASE3
First recorded
Jan 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sarepta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .